New York Times:
The race is on to vaccinate the nation’s nearly 17 million 12- to 15-year-olds against Covid-19.
The Food and Drug Administration’s decision on Monday to authorize the Pfizer-BioNTech vaccine for younger adolescents presents a new opportunity in the push for broad immunity against the coronavirus in the United States. But the challenges of getting them vaccinated are more complicated than for adults and older teenagers.